Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.

Détails

ID Serval
serval:BIB_5E31A5BEE4AD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.
Périodique
Blood
Auteur⸱e⸱s
Jantunen E., Boumendil A., Finel H., Luan J.J., Johnson P., Rambaldi A., Haynes A., Duchosal M.A., Bethge W., Biron P., Carlson K., Craddock C., Rudin C., Finke J., Salles G., Kroschinsky F., Sureda A., Dreger P.
Collaborateur⸱rice⸱s
on behalf of the Lymphoma Working Party of the EBMT
ISSN
1528-0020 (Electronic)
ISSN-L
0006-4971
Statut éditorial
Publié
Date de publication
2013
Volume
121
Numéro
13
Pages
2529-2532
Langue
anglais
Notes
Publication types: JOURNAL ARTICLE Publication Status: ppublish. PDF type: Brief Report
Résumé
Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EATL between 2000 and 2010. Thirty-one patients (70%) were in first complete or partial remission at the time of the ASCT. With a median follow-up of 46 months, relapse incidence, progression-free survival, and overall survival were 39%, 54%, and 59% at 4 years, respectively, with only one relapse occurring beyond 18 months posttransplant. There was a trend for better survival in patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062). ASCT is feasible in selected patients with EATL and can yield durable disease control in a significant proportion of the patients.
Pubmed
Web of science
Open Access
Oui
Création de la notice
20/03/2013 15:59
Dernière modification de la notice
20/08/2019 15:16
Données d'usage